Stock NHZHF NEW HORIZON HEALTH LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

New Horizon Health Limited Stock OTC Markets

Equities

NHZHF

KYG6485S1021

Medical Equipment, Supplies & Distribution

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for New Horizon Health Limited -.--% -.--%
04-08 New Horizon Health Limited Announces Board Appointments CI
03-28 New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 CI

Financials

Sales 2023 * 1.83B 253M 346M Sales 2024 * 2.85B 394M 538M Capitalization 5.86B 810M 1.11B
Net income 2023 * 13M 1.8M 2.46M Net income 2024 * 315M 43.52M 59.54M EV / Sales 2023 * 2.82 x
Net cash position 2023 * 695M 96.04M 131M Net cash position 2024 * 274M 37.92M 51.87M EV / Sales 2024 * 1.96 x
P/E ratio 2023 *
228 x
P/E ratio 2024 *
19 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 76.11%
More Fundamentals * Assessed data

Chart New Horizon Health Limited

Dynamic Chart

Latest news about New Horizon Health Limited

New Horizon Health Limited Announces Board Appointments CI
New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023 CI
New Horizon Health Forecasts Up to 168% Rise in 2023 Revenue MT
New Horizon Health Limited Provides Group Earnings Guidance for the Year Ended December 31, 2023 CI
New Horizon Health Swings to Profit in H1 as Revenue Soars 265% MT
New Horizon Health Limited commences an Equity Buyback Plan for 45,759,199 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023. CI
New Horizon Health Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
New Horizon Health Rejects Short Seller's Allegations MT
New Horizon Health Forecasts Swing to Profit in H1; Shares Plunge 9% MT
New Horizon Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023 CI
New Horizon Health Plans Up to HK$500 Million Share Repurchase MT
New Horizon Health Sees Up to 271% Increase in H1 Revenue MT
New Horizon Health Limited Provides Group Earnings Guidance for the Six Months Ended June 30, 2023 CI
New Horizon Health Grants Share Options, RSUs to Various Directors, Employees MT
New Horizon Health Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news

Analyst Recommendations on New Horizon Health Limited

UBS Adjusts New Horizon Health's Price Target to HK$51 From HK$47, Keeps at Buy MT
UBS Adjusts New Horizon Health’s Price Target to HK$47 From HK$52 Keeps at Buy MT
More recommendations

Press releases New Horizon Health Limited

Qiming Venture Partners' Portfolio Company UBTech Listed on Hong Kong Stock Exchange PR
EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong AQ
New Horizon cuts ribbon on cancer screening research center AQ
New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82% AQ
New Horizon Health Announces 2021 Interim Results: Revenue Increases 317% Year-on-year, Gross Profit Margin Climbs to 56.2% AQ
More press releases

News in other languages on New Horizon Health Limited

UPDATE/MÄRKTE ASIEN/Schanghai zum Wiederstart nur anfangs sehr fest
MÄRKTE ASIEN/Schanghai zum Wiederstart nur anfangs sehr fest
Westpac Banking : MÄRKTE ASIEN/Leichter - Schanghai zum Wiederstart fester
More news

Managers and Directors - New Horizon Health Limited

Managers TitleAgeSince
Ye Qing Zhu CEO
 Chief Executive Officer 52 18-06-06
Yi You Chen FOU
 Founder - 18-06-06
Yu Gao DFI
 Director of Finance/CFO 41 20-05-31
Members of the board TitleAgeSince
Yi You Chen FOU
 Founder - 18-06-06
Danke Yu BRD
 Director/Board Member 54 21-02-16
Na Xin Yao BRD
 Director/Board Member 54 20-10-08
More insiders

Company Profile

New Horizon Health Ltd is a China-based investment holding company principally engaged in the research, development, clinical development, test operation and commercialization of screening products for colorectal cancer, gastric cancer and cervical cancer. The Company distributes its ColoClear, Pupu tube and other products to customers through its own network, contracted sales organisations (CSOs) and Internet sales or e-platform operated by healthcare clinics. The Company’s Youyou Tube (a stool-based self-checking gastric cancer screening test) and CerviClear (a non-invasive urine cervical cancer home screening test) are under development.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-08-15 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for New Horizon Health Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.06 CNY
Average target price
29.36 CNY
Spread / Average Target
+124.77%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
BIOMÉRIEUX Stock bioMérieux
-4.22% 12.39B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-0.60% 8.43B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+7.25% 5.77B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+33.95% 5.76B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-10.21% 4.1B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+10.62% 2.66B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-60.35% 2.66B
VITROLIFE AB Stock Vitrolife AB
-7.50% 2.39B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+16.77% 2.02B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 6606 Stock
  4. NHZHF Stock